ArticleFrontiers in immunology2025
Remarkable increase in Interleukin-5 receptor expression beyond tissue eosinophils in inflammatory bowel disease.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammatory and Immune Cytoprofiles of Active Ulcerative Colitis from Crohn's Disease-Insights from Multivariable Modeling.International journal of molecular sciences · 2026Article
- Fundamental and emerging insights into innate and adaptive immunity in inflammatory bowel diseases.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The role of tissue eosinophils and their relationship with interleukin-5 in gastrointestinal disorders have not been elucidated. This study aimed to analyze tissue eosinophils and interleukin-5 receptor-α subunit (IL-5RA) expression on eosinophils in inflammatory bowel disease (IBD). Methods: Blood and stool test results and radiologic and endoscopic findings in pediatric patients, who were newly diagnosed with IBD, eosinophilic gastrointestinal diseases (EGIDs), or disorders of gut-brain interactions were retrospectively reviewed. Tissue eosinophil counts were analyzed, and immunohistochemistry was performed using an antibody against IL-5RA expressed on eosinophils in the colonic mucosa. Results: The tissue eosinophil count and IL-5RA-expressing eosinophil density were significantly different among the three groups ( Discussion: The expression of IL-5RA in tissue eosinophils is elevated in treatment naïve IBD. IL-5RA expression may reflect disease severity and its extent of involvement in early active CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.